Guardant Health up as cancer detection test gets FDA's 'breakthrough' tag

Guardant Health

03/06/2025 15:48

** Shares of medical diagnostics firm Guardant Health GH.O up 7.5% at $45.25

** GH says the U.S. FDA has granted "breakthrough" tag for its device to detect multiple types of cancer

** The multi-cancer detection (MCD) test uses a blood sample to screen for different cancer types in patients aged 45 or older

** FDA's breakthrough devices program is intended to provide patients and health care providers with timely access to medical devices by speeding up development, assessment, and review, according to its website

** Including session's move, stock up 46.8% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))